TrialID,url,Scientific_title,Conditions,Date_enrollment_format,control_arm,control_manual,study_arm,randomisation,blinding,subject_blind,caregiver_blind,investigator_blind,outcome_blind,analyst_blind,prospective,Source_registry,phase_clean,region_Africa,region_N_America,region_L_America,region_Asia,region_Europe,region_Oceania,multicentre,primary_purpose,sponsor_type,sample_size,vaccine,conventional,traditional,Bridging_flag,Study_design,Day_inferred,Date_registration_format,Phase,Public_title,Countries,Primary_sponsor,Interventions
NCT03884465,https://clinicaltrials.gov/show/NCT03884465,"A Two Part, Phase 2 Open-label, Multi-Centre, Dose Escalation Hemodynamic Study to Evaluate Dose-Response and Safety of Inhaled LIQ861 (Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Subjects",Pulmonary Arterial Hypertension,2019-11-11,Yes,No,main,No,No,No,No,No,No,No,Yes,CT.gov,Phase 2,No,No,No,No,Yes,No,Yes,Treatment,industry,32,NA,NA,NA,FALSE,Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).,FALSE,2019-03-04,Phase 2,Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil,France;Germany;France;Germany,"Liquidia Technologies, Inc.",Drug: Inhaled dry powder treprostinil (LIQ861)
